Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients | Zendy

Donald A. Molony | Zendy; Vidhya Parameswaran | Zendy; Linda Ficociello | Zendy; Claudy Mullon | Zendy; Robert J. Kossmann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sucroferric Oxyhydroxide as Part of Combination Phosphate Binder Therapy among Hemodialysis Patients

Author(s) -

Donald A. Molony,

Vidhya Parameswaran,

Linda Ficociello,

Claudy Mullon,

Robert J. Kossmann

Publication year - 2020

Publication title -

kidney360

Language(s) - English

Resource type - Journals

ISSN - 2641-7650

DOI - 10.34067/kid.0000332019

Subject(s) - discontinuation , medicine , phosphate binder , hemodialysis , phosphate , combination therapy , kidney disease , sevelamer , observational study , pill , urology , pharmacology , hyperphosphatemia , chemistry , organic chemistry

Combination therapy with multiple phosphate binders is prescribed to reduce elevated serum phosphorus (sP) concentrations among patients on maintenance hemodialysis. Sucroferric oxyhydroxide (SO), an iron-based phosphate binder, has demonstrated efficacy at reducing sP while also being associated with a low pill burden. Whereas the effects of SO monotherapy have been well characterized in clinical trials and observational cohorts, little is known about the effects of SO-containing combination therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research